Larimar Therapeutics Validates Skin Biomarker in FA
BALA CYNWYD, Pennsylvania, April 30, 2026 Larimar Therapeutics, Inc. announced the publication of new cross-species research supporting the use...
Neurology
Advertisement
Corcept Therapeutics Reports ALS Survival Breakthrough
REDWOOD CITY, California, April 30, 2026 Corcept Therapeutics Incorporated announced compelling two-year overall survival data from its Phase 2...
Neurocrine Defines TDIS Threshold for TD Treatment Impact
SAN DIEGO, California, April 29, 2026 Neurocrine Biosciences announced the publication of new peer-reviewed research in The Journal of...
Novartis Itvisma Gains CHMP Boost for SMA Therapy
Basel, Switzerland | April 24, 2026 In a major breakthrough for rare disease treatment, Novartis has received a positive...
Johnson & Johnson IMAAVY Delivers 2-Year gMG Control
HORSHAM, Pa., April 22, 2026 Johnson & Johnson has reported compelling long-term Phase 3 data demonstrating that IMAAVY® (nipocalimab-aahu)...
Advertisements
Roche ENSPRYNG Shows MOGAD Clinical Benefit Data
BASEL, Switzerland, April 2026 Roche reported new clinical findings demonstrating the effectiveness of ENSPRYNG® (satralizumab) in reducing relapse risk...
Monopar Reports Phase 3 ALXN1840 Data at AAN 2026
WILMETTE, Ill., April 19, 2026 Monopar Therapeutics announced new Phase 3 clinical data demonstrating greater neurologic benefit of ALXN1840...
Mapi Pharma GA Depot Shows Strong MS Progression Control
NESS ZIONA, Israel, April 16, 2026 Mapi Pharma Ltd. has announced new clinical findings demonstrating that its Glatiramer Acetate...
Neurelis Shows Strong Seizure Control Data for VALTOCO at AAN
SAN DIEGO, Calif., April 16, 2026 Neurelis, Inc. has announced new clinical and real-world analyses demonstrating the effectiveness of...
MemorialCare Joins FASTEST Trial for Stroke Therapy
LONG BEACH, Calif., April 2026 MemorialCare Long Beach Medical Center has joined a nationwide Phase 3 clinical research effort...
Advertisement
